|
1
|
Yang Y, Jiang Q, Zhang F. Nanocrystals for Deep-Tissue In Vivo Luminescence Imaging in the Near-Infrared Region. Chem Rev 2024; 124:554-628. [PMID: 37991799 DOI: 10.1021/acs.chemrev.3c00506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2023]
Abstract
In vivo imaging technologies have emerged as a powerful tool for both fundamental research and clinical practice. In particular, luminescence imaging in the tissue-transparent near-infrared (NIR, 700-1700 nm) region offers tremendous potential for visualizing biological architectures and pathophysiological events in living subjects with deep tissue penetration and high imaging contrast owing to the reduced light-tissue interactions of absorption, scattering, and autofluorescence. The distinctive quantum effects of nanocrystals have been harnessed to achieve exceptional photophysical properties, establishing them as a promising category of luminescent probes. In this comprehensive review, the interactions between light and biological tissues, as well as the advantages of NIR light for in vivo luminescence imaging, are initially elaborated. Subsequently, we focus on achieving deep tissue penetration and improved imaging contrast by optimizing the performance of nanocrystal fluorophores. The ingenious design strategies of NIR nanocrystal probes are discussed, along with their respective biomedical applications in versatile in vivo luminescence imaging modalities. Finally, thought-provoking reflections on the challenges and prospects for future clinical translation of nanocrystal-based in vivo luminescence imaging in the NIR region are wisely provided.
Collapse
Affiliation(s)
- Yang Yang
- College of Energy Materials and Chemistry, State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, Hohhot 010021, China
| | - Qunying Jiang
- College of Energy Materials and Chemistry, State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, Hohhot 010021, China
| | - Fan Zhang
- College of Energy Materials and Chemistry, State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, Hohhot 010021, China
- Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Fudan University, Shanghai 200433, China
| |
Collapse
|
|
2
|
Pan C, Gao Q, Kim BS, Han Y, Gao G. The Biofabrication of Diseased Artery In Vitro Models. MICROMACHINES 2022; 13:mi13020326. [PMID: 35208450 PMCID: PMC8874977 DOI: 10.3390/mi13020326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 02/10/2022] [Accepted: 02/17/2022] [Indexed: 11/16/2022]
Abstract
As the leading causes of global death, cardiovascular diseases are generally initiated by artery-related disorders such as atherosclerosis, thrombosis, and aneurysm. Although clinical treatments have been developed to rescue patients suffering from artery-related disorders, the underlying pathologies of these arterial abnormalities are not fully understood. Biofabrication techniques pave the way to constructing diseased artery in vitro models using human vascular cells, biomaterials, and biomolecules, which are capable of recapitulating arterial pathophysiology with superior performance compared with conventional planar cell culture and experimental animal models. This review discusses the critical elements in the arterial microenvironment which are important considerations for recreating biomimetic human arteries with the desired disorders in vitro. Afterward, conventionally biofabricated platforms for the investigation of arterial diseases are summarized, along with their merits and shortcomings, followed by a comprehensive review of advanced biofabrication techniques and the progress of their applications in establishing diseased artery models.
Collapse
Affiliation(s)
- Chen Pan
- Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, China; (C.P.); (Q.G.)
- School of Mechanical Engineering, Beijing Institute of Technology, Beijing 100081, China;
| | - Qiqi Gao
- Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, China; (C.P.); (Q.G.)
- School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China
| | - Byoung-Soo Kim
- School of Biomedical Convergence Engineering, Pusan National University, Yangsan 626841, Korea
- Correspondence: (B.-S.K.); (G.G.)
| | - Yafeng Han
- School of Mechanical Engineering, Beijing Institute of Technology, Beijing 100081, China;
| | - Ge Gao
- Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, China; (C.P.); (Q.G.)
- School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China
- Correspondence: (B.-S.K.); (G.G.)
| |
Collapse
|
|
3
|
Nestele JA, Rohlfing AK, Dicenta V, Bild A, Eißler D, Emschermann F, Kremser M, Krutzke K, Schäffer TE, Borst O, Levi M, Korin N, Gawaz MP. Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation. Int J Mol Sci 2021; 23:11. [PMID: 35008437 PMCID: PMC8744670 DOI: 10.3390/ijms23010011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/17/2021] [Accepted: 12/18/2021] [Indexed: 11/19/2022] Open
Abstract
Traditional antithrombotic agents commonly share a therapy-limiting side effect, as they increase the overall systemic bleeding risk. A novel approach for targeted antithrombotic therapy is nanoparticles. In other therapeutic fields, nanoparticles have enabled site-specific delivery with low levels of toxicity and side effects. Here, we paired nanotechnology with an established dimeric glycoprotein VI-Fc (GPVI-Fc) and a GPVI-CD39 fusion protein, thereby combining site-specific delivery and new antithrombotic drugs. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles, NP-BSA, NP-GPVI and NP-GPVI-CD39 were characterized through electron microscopy, atomic force measurements and flow cytometry. Light transmission aggregometry enabled analysis of platelet aggregation. Thrombus formation was observed through flow chamber experiments. NP-GPVI and NP-GPVI-CD39 displayed a characteristic surface coating pattern. Fluorescence properties were identical amongst all samples. NP-GPVI and NP-GPVI-CD39 significantly impaired platelet aggregation. Thrombus formation was significantly impaired by NP-GPVI and was particularly impaired by NP-GPVI-CD39. The receptor-coated nanoparticles NP-GPVI and the bifunctional molecule NP-GPVI-CD39 demonstrated significant inhibition of in vitro thrombus formation. Consequently, the nanoparticle-mediated antithrombotic effect of GPVI-Fc, as well as GPVI-CD39, and an additive impact of CD39 was confirmed. In conclusion, NP-GPVI and NP-GPVI-CD39 may serve as a promising foundation for a novel therapeutic approach regarding targeted antithrombotic therapy.
Collapse
Affiliation(s)
- Jeremy A. Nestele
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| | - Anne-Katrin Rohlfing
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| | - Valerie Dicenta
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| | - Alexander Bild
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| | - Daniela Eißler
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
- DFG Heisenberg Group Thrombocardiology, University of Tübingen, 72076 Tubingen, Germany
| | - Frederic Emschermann
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| | - Marcel Kremser
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| | - Konstantin Krutzke
- Institute for Applied Physics, University of Tübingen, 72076 Tubingen, Germany; (K.K.); (T.E.S.)
| | - Tilman E. Schäffer
- Institute for Applied Physics, University of Tübingen, 72076 Tubingen, Germany; (K.K.); (T.E.S.)
| | - Oliver Borst
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
- DFG Heisenberg Group Thrombocardiology, University of Tübingen, 72076 Tubingen, Germany
| | - Moran Levi
- Department of Biomedical Engineering, Technion, Israel Institute of Technology, Haifa 3200003, Israel; (M.L.); (N.K.)
| | - Netanel Korin
- Department of Biomedical Engineering, Technion, Israel Institute of Technology, Haifa 3200003, Israel; (M.L.); (N.K.)
| | - Meinrad Paul Gawaz
- Department of Cardiology and Angiology, University of Tübingen, 72076 Tubingen, Germany; (J.A.N.); (A.-K.R.); (V.D.); (A.B.); (D.E.); (F.E.); (M.K.); (O.B.)
| |
Collapse
|